BIPAR SCIENCES TO PRESENT AT PACIFIC GROWTH EQUITIES LIFE
SCIENCE GROWTH CONFERENCE ON JUNE 14, 2006
Brisbane, CA – June 7, 2006 – BiPar Sciences, Inc., a clinical-stage biopharmaceutical company, today announced that Thomas F. White, President and Chief Executive Officer will present at the Pacific Growth Equities Life Sciences Growth Conference on Wednesday, June 14, at 8:30 a.m. at the InterContinental Mark Hopkins Hotel in San Francisco.
Mr. White will provide an overview of the Company’s strategy to develop and commercialize a new class of cancer therapies and discuss its lead product candidate, BSI-201. BSI-201 is a potent, novel inhibitor of PARP (poly-adenylribose polymerase), an important regulator of cell proliferation, gene transcription and DNA repair. It is currently being evaluated in an open-label, dose escalation clinical study at MD Anderson Cancer Center in Houston and the Institute for Drug Development in San Antonio. BSI-201selectively induces tumor cell death by inhibiting enzyme function central to tumor survival. In numerous preclinical studies, it was shown to be well tolerated and exhibited activity against a broad range of tumor types, including but not limited to ovarian, prostate, breast, colon, lung, pancreatic, cervical and bladder.
About BiPar Sciences
BiPar Sciences Inc. (www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to meet the significant unmet needs of cancer patients. The Company’s lead product candidate is BSI-201, which is now in early-stage clinical testing for advanced malignancies. The Company will be evaluating the potential of BSI-201 in multiple cancers, and is developing additional cancer drug candidates, all of which were discovered by researchers from the University of California, San Francisco.